S100A9 and metabolic dysfunction-associated steatohepatitis: This study thus focuses on S100A9 and MYH2 to establish a blood-based, non-invasive diagnostic approach and to explore relevant therapeutic strategies, contributing to improved clinical management of COPD-associated NASH.